Morgan Cheatham

Vice President, Bessemer Venture Partners
Board Member, Coalition for Health AI (CHAI)

Morgan Cheatham is a Vice President with Bessemer Venture Partners where he leads healthcare and life sciences investments from seed to growth stages. He focuses across the value chain spanning software, therapeutics, services, and diagnostics, to improve patient care from bench to bedside and specializes in applications of computation in biomedicine.

Select investments in his portfolio include Abridge, Hinge Health, Headspace Health (fka Ginger), Subtle Medical, Turquoise Health, Productboard, Plenful, Groups Recover Together, Ansible Health, Seismic Therapeutic, and FOLX Health, where he serves on the board and previously served as Interim CEO. He was awarded Forbes 30U30 for Venture Capital and the National Venture Capital Association Rising Star Award in 2023.

Morgan is pursuing medical training at The Warren Alpert Medical School of Brown University with a focus on genomics and AI. His research collaborations include the Stanford Institute for Human-Centered AI, Harvard Department of Biomedical Informatics, and the National Human Genome Research Institute. He is a Board Director at the Coalition for Health AI and a member of the New England Journal of Medicine Artificial Intelligence Editorial Team. He earned his bachelor of science from Brown University.